Waystar Weighs Sale Amid Software Sector Challenges

Waystar, a prominent player in healthcare software, is reportedly exploring strategic options, including a potential sale, according to sources familiar with the situation. This move comes as the company grapples with a 24% decrease in its stock value this year amid broader challenges in the software sector.

Investment Bank Evercore Engaged

Based in Lehi, Utah, and Louisville, Kentucky, Waystar has enlisted the help of investment bank Evercore to navigate this process. The discussions are in preliminary stages, and as with any such exploration, plans may evolve, and a sale may not ultimately occur. Both Waystar and Evercore have declined to comment on these developments.

Waystar's current market valuation stands at approximately $4.8 billion, a downturn that reflects investor concerns about the software industry's future, particularly with the rise of artificial intelligence. The company initially saw its shares climb from $20 to a peak of $45 in 2025, driven by its positioning as a technology firm focused on automating administrative healthcare tasks. However, shifts in market sentiment have since put pressure on its stock price.

Origins and Ownership

Formed in 2017 through the merger of Zirmed and Navicure, Waystar has become a significant entity in healthcare revenue management. Its major shareholders include EQT, which holds a 13% stake, followed by the Canada Pension Plan Investment Board (CPPIB) at 10% and BlackRock Institutional Trust Company at 8%, according to data from LSEG. EQT, CPPIB, and BlackRock have all refrained from commenting on the current situation.

Waystar's strategy has been to market itself as a software company rather than a service provider, aiming to capitalize on the higher valuations typically granted to tech firms. This positioning helped attract investor interest initially but has faced challenges as market dynamics shift.

Future Prospects Under Review

The potential sale could serve as a barometer for investor interest in software companies amidst the current economic climate. Analysts at Morgan Stanley noted in a July report that investors are wary of the impact artificial intelligence could have on traditional software models, which may have contributed to the pressure on Waystar's stock.

As Waystar evaluates its options, the outcome will likely have significant implications for its stakeholders and the broader software sector. A successful sale could signal a renewed interest in healthcare technology firms, while an unsuccessful attempt might underscore ongoing investor caution.